Annual EBIT
-$28.11 M
+$9.35 M+24.95%
December 31, 2023
Summary
- As of February 8, 2025, AVTX annual earnings before interest & taxes is -$28.11 million, with the most recent change of +$9.35 million (+24.95%) on December 31, 2023.
- During the last 3 years, AVTX annual EBIT has risen by +$19.18 million (+40.56%).
- AVTX annual EBIT is now -302.40% below its all-time high of $13.89 million, reached on December 31, 2017.
Performance
AVTX EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$12.86 M
-$3.39 M-35.78%
September 30, 2024
Summary
- As of February 8, 2025, AVTX quarterly earnings before interest & taxes is -$12.86 million, with the most recent change of -$3.39 million (-35.78%) on September 30, 2024.
- Over the past year, AVTX quarterly EBIT has dropped by -$3.39 million (-35.78%).
- AVTX quarterly EBIT is now -158.67% below its all-time high of $21.92 million, reached on September 30, 2017.
Performance
AVTX Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$35.98 M
-$9.11 M-33.91%
September 30, 2024
Summary
- As of February 8, 2025, AVTX TTM earnings before interest & taxes is -$35.98 million, with the most recent change of -$9.11 million (-33.91%) on September 30, 2024.
- Over the past year, AVTX TTM EBIT has dropped by -$9.11 million (-33.91%).
- AVTX TTM EBIT is now -317.27% below its all-time high of $16.56 million, reached on September 30, 2017.
Performance
AVTX TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
AVTX EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +24.9% | -35.8% | -33.9% |
| 3 y3 years | +40.6% | -45.2% | +4.0% |
| 5 y5 years | -88.6% | -349.4% | +4.0% |
AVTX EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +65.8% | -414.1% | +38.4% | -72.1% | +56.2% |
| 5 y | 5-year | -61.6% | +65.8% | -414.1% | +57.9% | -106.9% | +56.2% |
| alltime | all time | -302.4% | +65.8% | -158.7% | +57.9% | -317.3% | +56.2% |
Avalo Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$12.86 M(+35.8%) | -$35.98 M(+33.9%) |
| Jun 2024 | - | -$9.47 M(+81.1%) | -$26.87 M(+9.5%) |
| Mar 2024 | - | -$5.23 M(-37.9%) | -$24.55 M(-13.3%) |
| Dec 2023 | -$28.11 M(-25.0%) | -$8.42 M(+124.5%) | -$28.32 M(-1.5%) |
| Sep 2023 | - | -$3.75 M(-47.6%) | -$28.75 M(+37.5%) |
| Jun 2023 | - | -$7.15 M(-20.5%) | -$20.91 M(-18.3%) |
| Mar 2023 | - | -$9.00 M(+1.6%) | -$25.59 M(-31.7%) |
| Dec 2022 | -$37.46 M(-54.4%) | -$8.86 M(-316.2%) | -$37.46 M(-19.6%) |
| Sep 2022 | - | $4.09 M(-134.6%) | -$46.57 M(-30.6%) |
| Jun 2022 | - | -$11.83 M(-43.3%) | -$67.14 M(-7.3%) |
| Mar 2022 | - | -$20.87 M(+16.2%) | -$72.45 M(-11.8%) |
| Dec 2021 | -$82.15 M(+73.7%) | -$17.96 M(+9.0%) | -$82.16 M(+35.5%) |
| Sep 2021 | - | -$16.48 M(-3.8%) | -$60.64 M(+5.6%) |
| Jun 2021 | - | -$17.13 M(-44.0%) | -$57.42 M(+10.2%) |
| Mar 2021 | - | -$30.58 M(-960.2%) | -$52.10 M(+90.3%) |
| Dec 2020 | -$47.29 M(+171.9%) | $3.56 M(-126.8%) | -$27.38 M(-25.3%) |
| Sep 2020 | - | -$13.26 M(+12.2%) | -$36.66 M(+39.6%) |
| Jun 2020 | - | -$11.81 M(+101.5%) | -$26.26 M(+43.7%) |
| Mar 2020 | - | -$5.86 M(+2.5%) | -$18.27 M(+5.1%) |
| Dec 2019 | -$17.39 M | -$5.72 M(+100.0%) | -$17.39 M(+27.0%) |
| Sep 2019 | - | -$2.86 M(-25.2%) | -$13.70 M(-15.3%) |
| Jun 2019 | - | -$3.83 M(-23.2%) | -$16.18 M(-1.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$4.98 M(+145.6%) | -$16.40 M(+10.0%) |
| Dec 2018 | -$14.90 M(-207.3%) | -$2.03 M(-62.0%) | -$14.90 M(-13.5%) |
| Sep 2018 | - | -$5.34 M(+32.4%) | -$17.23 M(-271.7%) |
| Jun 2018 | - | -$4.04 M(+15.6%) | $10.03 M(-18.4%) |
| Mar 2018 | - | -$3.49 M(-19.9%) | $12.30 M(-11.5%) |
| Dec 2017 | $13.89 M(-186.4%) | -$4.36 M(-119.9%) | $13.89 M(-16.1%) |
| Sep 2017 | - | $21.92 M(-1335.0%) | $16.56 M(-246.2%) |
| Jun 2017 | - | -$1.77 M(-6.5%) | -$11.32 M(-13.1%) |
| Mar 2017 | - | -$1.90 M(+12.6%) | -$13.04 M(-18.9%) |
| Dec 2016 | -$16.08 M(+46.1%) | -$1.69 M(-71.7%) | -$16.08 M(-11.0%) |
| Sep 2016 | - | -$5.96 M(+71.0%) | -$18.07 M(+28.5%) |
| Jun 2016 | - | -$3.49 M(-29.4%) | -$14.06 M(+4.4%) |
| Mar 2016 | - | -$4.94 M(+34.5%) | -$13.47 M(+22.3%) |
| Dec 2015 | -$11.01 M(-35.7%) | -$3.68 M(+87.6%) | -$11.01 M(-1.4%) |
| Sep 2015 | - | -$1.96 M(-32.2%) | -$11.17 M(-26.6%) |
| Jun 2015 | - | -$2.89 M(+16.4%) | -$15.21 M(-4.8%) |
| Mar 2015 | - | -$2.48 M(-35.2%) | -$15.97 M(-6.7%) |
| Dec 2014 | -$17.12 M(+32.3%) | -$3.83 M(-36.1%) | -$17.12 M(+28.9%) |
| Sep 2014 | - | -$6.00 M(+64.1%) | -$13.28 M(+82.3%) |
| Jun 2014 | - | -$3.66 M(+0.7%) | -$7.28 M(+100.7%) |
| Mar 2014 | - | -$3.63 M | -$3.63 M |
| Dec 2013 | -$12.93 M | - | - |
FAQ
- What is Avalo Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Avalo Therapeutics?
- What is Avalo Therapeutics annual EBIT year-on-year change?
- What is Avalo Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Avalo Therapeutics?
- What is Avalo Therapeutics quarterly EBIT year-on-year change?
- What is Avalo Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Avalo Therapeutics?
- What is Avalo Therapeutics TTM EBIT year-on-year change?
What is Avalo Therapeutics annual earnings before interest & taxes?
The current annual EBIT of AVTX is -$28.11 M
What is the all time high annual EBIT for Avalo Therapeutics?
Avalo Therapeutics all-time high annual earnings before interest & taxes is $13.89 M
What is Avalo Therapeutics annual EBIT year-on-year change?
Over the past year, AVTX annual earnings before interest & taxes has changed by +$9.35 M (+24.95%)
What is Avalo Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of AVTX is -$12.86 M
What is the all time high quarterly EBIT for Avalo Therapeutics?
Avalo Therapeutics all-time high quarterly earnings before interest & taxes is $21.92 M
What is Avalo Therapeutics quarterly EBIT year-on-year change?
Over the past year, AVTX quarterly earnings before interest & taxes has changed by -$3.39 M (-35.78%)
What is Avalo Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of AVTX is -$35.98 M
What is the all time high TTM EBIT for Avalo Therapeutics?
Avalo Therapeutics all-time high TTM earnings before interest & taxes is $16.56 M
What is Avalo Therapeutics TTM EBIT year-on-year change?
Over the past year, AVTX TTM earnings before interest & taxes has changed by -$9.11 M (-33.91%)